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astrocytes leads to more severe brain damage
and vasospasm after subarachnoid hemorrhage
Patrick KK Yeung1, Jiangang Shen2, Stephen SM Chung4 and Sookja K Chung1,3,5*Abstract
Background: Endothelin-1 (ET-1) is a potent vasoconstrictor, and astrocytic ET-1 is reported to play a role in the
pathogenesis of cerebral ischemic injury and cytotoxic edema. However, it is still unknown whether astrocytic ET-1
also contributes to vasogenic edema and vasospasm during subarachnoid hemorrhage (SAH). In the present study,
transgenic mice with astrocytic endothelin-1 over-expression (GET-1 mice) were used to investigate the
pathophysiological role of ET-1 in SAH pathogenesis.
Results: The GET-1 mice experienced a higher mortality rate and significantly more severe neurological deficits,
blood–brain barrier breakdown and vasogenic edema compared to the non-transgenic (Ntg) mice following SAH.
Oral administration of vasopressin V1a receptor antagonist, SR 49059, significantly reduced the cerebral water
content in the GET-1 mice. Furthermore, the GET-1 mice showed significantly more pronounced middle cerebral
arterial (MCA) constriction after SAH. Immunocytochemical analysis showed that the calcium-activated potassium
channels and the phospho-eNOS were significantly downregulated, whereas PKC-α expression was significantly
upregulated in the MCA of the GET-1 mice when compared to Ntg mice after SAH. Administration of ABT-627
(ETA receptor antagonist) significantly down-regulated PKC-α expression in the MCA of the GET-1 mice following SAH.
Conclusions: The present study suggests that astrocytic ET-1 involves in SAH-induced cerebral injury, edema and
vasospasm, through ETA receptor and PKC-mediated potassium channel dysfunction. Administration of ABT-627
(ETA receptor antagonist) and SR 49059 (vasopressin V1a receptor antagonist) resulted in amelioration of edema and
vasospasm in mice following SAH. These data provide a strong rationale to investigate SR 49059 and ABT-627 as
therapeutic drugs for the treatment of SAH patients.
Keywords: Subarachnoid hemorrhage, Vasospasm, Endothelium, Astrocytes, Brain edemaBackground
Subarachnoid hemorrhage (SAH) is a subset of stroke,
which occurs due to bleeding between the brain and the
meninges in the subarachnoid space. Patients with SAH
suffer from fatal complications, such as rapid develop-
ment of cerebral vasogenic brain edema, and rise of
intracranial pressure, mainly due to hematoma [1]. One
third of patients with SAH also suffer from secondary
ischemia due to the delayed narrowing of intracranial* Correspondence: skchung@hkucc.hku.hk
1Department of Anatomy, Li Ka Shing Faculty of Medicine, The University of
Hong Kong, Hong Kong SAR, China
3Research Center of Heart, Brain, Hormone and Healthy Aging, The University
of Hong Kong, Hong Kong, SAR, China
Full list of author information is available at the end of the article
© 2013 Yeung et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orarteries (vasospasm). Vasospasm results in the interrup-
tion of blood flow to the vital parts of the brain causing
morbidity and mortality in up to 30% patients [2]. Vaso-
pressin receptor (V1 or V2) antagonists have been evalu-
ated in numerous studies using different brain injury
paradigms to investigate their effects on attenuating
edema development after brain injury in animal models
[3-5]. Until now, the pathophysiological aspects and
mechanisms of SAH-induced vasospasm have not been
completely elucidated, and the treatment for SAH-
induced vasospasm remains one of the major challenges
in neurosurgery.
Break down of red blood cells and release of oxyhemo-
globin is the putative cause of delayed vasospasm after
SAH [6-9]. One of the oxyhemoglobin-mediated cerebralLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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constricting agent, endothelin-1 (ET-1) [10,11]. ET-1 is a
potent vasoconstrictor originally isolated from aortic
endothelial cells. However, ET-1 has also been detected
in several other types of brain cells, including endothe-
lial cells, neurons and astrocytes [12-14]. It has been
demonstrated that activated mononuclear leukocytes are
involved in ET-1 production under SAH [15]. Addition-
ally, the release of ET-1 can be stimulated by oxyhemo-
globlin or thrombin in endothelial and smooth muscle
cells [16]. However, it is still unclear whether astrocytic
ET-1 and the mechanisms of its release are responsible
for cerebral vasospasm development. Several clinical
studies have established a correlation between elevated
ET-1 levels in plasma and cerebral spinal fluid, and cere-
bral vasospasm-mediated ischemic damage after SAH
[17-19], indicating that ET-1 may also be produced dur-
ing delayed ischemia after SAH.
Astrocytic ET-1 has been shown to play a role in the
pathogenesis of cerebral ischemic injury. Previously, we
have demonstrated that transgenic mice (GET-1 mice)
that over-express endothelin-1 (ET-1) specifically in the
astrocytes are more susceptible to brain damage, includ-
ing increased infarct volume, hemispheric swelling as
well as cerebral water content, upon transient focal is-
chemia induced by middle cerebral artery occlusion
(MCAO). We have also demonstrated that GET-1 mice
develop more severe cytotoxic edema when induced by
water intoxication [20,21]. However, it is still unclear
whether astrocytic ET-1 also plays an important role in
vasogenic edema formation.
In the present study, transgenic mice with astrocytic
endothelin-1 (GET-1 mice) over-expression were used to
investigate the pathophysiological role(s) of ET-1 in SAH
pathogenesis with the aim of dissecting the mechanisms
involved in the formation of secondary ischemia in SAH.
A better understanding of the molecular mechanisms in-
volved in SAH formation may help in formulation of
therapeutic strategies for the treatment and management
of the disease.
Methods
Mouse subarachnoid hemorrhage model
Both Ntg and GET-1 mice were housed under controlled
diurnal lighting conditions and allowed free access to
food and water. The protocol of this study was reviewed
and approved by the Committee on the Use of Live
Animals in Teaching and Research in the University of
Hong Kong.
SAH was induced in mice by the artery puncture
method as previously described [22]. In brief, age-
matched Ntg or GET-1 mice were anesthetized with gas
(2% halothane in 70% N2O/30% O2 for induction and
1% halothane in 70% N2O/30% O2 for maintenance)[23]. Regional cerebral blood flow (rCBF) was monitored
and recorded with a Laser-Doppler system (PeriFlux
5001 and Perisoft software) during the whole surgical
procedure to confirm successful SAH induction. The
average value of rCBF was recorded one minute before
induction of SAH served as the control value. SAH was
induced, and rCBF was recorded for 20 minutes after
SAH induction. The rectal temperature was maintained
at 37 ± 0.5°C with a temperature control system (FHC,
Brunswick, ME, USA). The right carotid artery was iden-
tified along with all its extracranial branches, and the ex-
ternal carotid artery was dissected. A sharpened 5–0
monofilament suture was advanced into the external ca-
rotid artery past the common carotid bifurcation and
into the internal carotid artery. The suture was advanced
distally into the intracranial internal carotid artery until
resistance was felt and then pushed 3 mm further
through the right anterior cerebral artery (ACA) near
its intracranial bifurcation. The suture was then with-
drawn into the external carotid artery immediately,
which allowed reperfusion of the right internal carotid
artery (ICA) leading to SAH. After the surgery, the mice
were returned to the Intensive Care Unit (ICU) to facili-
tate recovery from anesthesia.
Neurological evaluation following SAH
A subset of animals was used for neurological evaluation
in the SAH experiment. A 100-point neurological scor-
ing system (scoring scale 0 to 100), which assessed the
general behavioral deficit, cranial nerve reflexes deficit,
motor deficit, sensory deficit and coordination deficit,
was used to evaluate the neurological deficit of mice
24 hours after SAH and continued for three days [24]. A
general behavioral score (0–40) was derived from spon-
taneous activity and respirations. A cranial nerve reflex
score (0–20) was derived from examination of olfactory,
vision, blinding reflex, whisker movement and hearing
response to stimulus. A motor score (0–10) was derived
from examination of symmetry of limb movement. A
sensory score (0–10) was derived from the response of
mice while their tails were being pinched. A coordin-
ation score (0–20) was derived from examination of
traveling ledge balance, righting reflex, front paws reach-
ing and retreatment response. Mice were sacrificed
afterwards and brain tissues were collected for further
analysis. The behavioral tests were performed blinded to
the genotypes.
Perfusion-fixation and vascular diameter measurement
At 72 hours after SAH induction, when vasospasm has
been reported to peak in mice models [25], cerebral
vascular perfusion and vascular diameter measurement
were performed as described previously [26]. After
neurological deficit evaluation, mice were anesthetized.
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with a blunted 20-gauge needle. Flexible plastic tubing
connected to the needle was used to deliver infusion so-
lutions by manual pulsatile syringe pressure, and the
tubing was connected to a 30-ml syringe. An incision
was made in the right atrium to allow outflow of perfu-
sion solutions. 20 ml of 0.9% NaCl was infused followed
by 10% formalin and gelatin-india ink solution. The dead
mice were refrigerated for 24 hours to allow gelatin so-
lidification, and thereafter the brains were harvested
and stored in 4% neutral buffered formaldehyde. The
cerebral vasculature was photographed by using a
video-linked microscope (Fluorescence Stereo Micro-
scope, MZ FLIII, Leica). At 72 hours after SAH induc-
tion, the diameter of the left and right MCA was
measured at the site 1 mm distal to the MCA-ACA bi-
furcation [27]. All procedures were performed blinded
to the genotypes.
Water content measurement
Different groups of animals were used for the water
content measurement. Brain tissue was removed for the
brain water content analysis at 24 hours after SAH. The
brain was weighted immediately to obtain the wet
weight. The brain was then dried in an oven at 105°C
for 48 hours and weighed again to obtain the dry weight.
The percentage of water content was calculated as [(wet
weight-dry weight)/wet weight] × 100% [28].
Evans Blue extravasation
Different groups of animals were used for the Evans Blue
(EB) extravasation. On Day 3 (72 hours) after SAH in-
duction, 0.1 ml of 4% EB in saline was injected intraven-
ously into the mice and allowed to circulate for 3 hours
[29]. For extraction of EB from brain, the brain was
placed in 1 ml PBS and homogenized by sonication. The
homogenate was centrifuged at 15,000 rpm for 30 mins
and 0.5 ml supernatant was added to an equal volume of
trichloroacetic acid. The mixture was incubated at 4°C
overnight and centrifuged at 15,000 g at 4°C for 30 mins
after incubation. The supernatant was collected, and EB
was measured at an excitation wavelength of 620 nm
and an emission wavelength of 680 nm using a fluores-
cence spectrophotometer. EB concentrations were calcu-
lated using the standard curve, and expressed as μg/g
brain tissue [30].
Immunocytochemical (ICC) analysis
On Day 3 after SAH induction, brain samples were col-
lected after neurological evaluation, and fixed with 4%
paraformaldehyde. MCA was isolated according to a
published protocol [31]. In brief, the first cut was made
at the groove between the forebrain and cerebellum
(−4.5 mm from bregma), then the second cutat −6.5 mm from bregma, and the final cut at 3 mm an-
terior to the groove (−1.5 mm from bregma). The anter-
ior portion of the forebrain was then turned 90° and two
sagittal cuts were made at the midline crossing the
olfactory tract to expose the cross section of the MCA
[31]. 7 μm thick coronal brain slices were used for the
ICC study. Brain sections were incubated with antibodies
against GFAP (1:2000, Z0334, DAKO, Carpinteria, CA,
USA), nNOS (1:200, 610310, BD Transduction Lab.,
USA), eNOS (1:200, 610298, BD Transduction Lab., USA),
p-eNOS (1:100, 9571, Cell Signaling Technology, USA),
ETAR (1:100, 324758, Calbichem, Merck, Germany), Maxi
K+α (1:500, 444910, Cabiochem, Merck, Germany ), PKC-
α (1:500, abcam ab4124, UK) and endothelin 1 (1:250,
abcam ab2786, UK). Signals were visualized by Vectastain
ABC kit (Vector Laboratories, Burlingame, CA, USA) with
3,3’-diaminobenzidine tetrahydrochloride (Zymed, South
San Francisco, CA, USA). All the conditions were followed
as described in our previous study [20].
Quantification of ICC photomicrographs
Pictures of the brain sections with positive staining
(GFAP: magnified 50×; MCA: magnified 100×) were ana-
lyzed with the software ImageJ [32]. For analyzing the
staining of the MCA, the entire vascular wall of the
MCA with staining was marked and the intensity of the
staining was measured [33]. The value was expressed as
mean ± SEM. All immunocytochemical photomicrograph
quantifications were performed in a blinded manner and
the results were expressed relative to Ntg sham group,
which were arbitrarily assigned a value of 100%.
Western blot analysis
Proteins were extracted from the brains of sham and
SAH groups of Ntg and GET-1 mice after 3 days. The
brain tissues were homogenized in ice-cold lysis buffer
(50 mM Tris–HCl, pH 8.8, 150 mM NaCl, 5 mM EDTA,
0.5% sodium deoxycholate, 0.5% NP-40, plus proteinase
inhibitor cocktail). Homogenate was centrifuged at 4°C,
3000 g for 5 mins, and the supernatant was used for the
Western blot analysis. Blots were incubated with anti-
bodies against PKC-α (1:500, ab4124, abcam, UK),
phospho-PKC-α (1:1000, Cat. no. #9375, Cell Signaling)
and α-tubulin (1:5000, sc-5286, Santa Cruz). Signals
were visualized by ECL (Amersham) and quantitated
using PhotoImager (Molecular Dynamics). Values for
protein levels were given as relative percentage to Ntg
sham group after normalization with individual
α-tubulin levels for equal loading.
Drug treatments
For the drug treatment, ETA receptor antagonist, ABT-
627, was dissolved in 0.25 M NaCO3. Both Ntg and
GET-1 mice received an intraperitoneal injection of
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gift from Dr. Ruth Wu-Wong), 5 mins after onset of
SAH. For the vasopressin V1a receptor antagonist treat-
ment, SR 49059 was dissolved in 10% DMSO. The mice
received an intraperitoneal injection of 30 mg/kg
SR 49059, 5 mins after SAH. The dosage concentration
used was similar to the effective dosage concentration
used in a previous study [34]. For all the drug tests,
vehicle-treated mice were used as controls.
Results
GET-1 mice had a higher death rate than the Ntg mice
after SAH
The survival rate of Ntg, and GET-1 mice was 100% and
77%, respectively, 24 hours after SAH. The survival rate
of Ntg mice decreased steadily on Day 2 (90%) and Day
3 (80%) after SAH. However, GET-1 mice showed a sub-
stantial drop in the survival rate, 61% and 54% on Day 2
and Day 3, respectively. GET-1 mice were more suscep-
tible to SAH damage with a death rate of about 50%
three days after SAH (Figure 1A).
Laser-doppler flowmetry
Upon subarachnoid hemorrhage induction, there was a
dramatic and immediate decrease in cerebral perfusion
(to < 20% of baseline) in both Ntg and GET-1 mice
(Figure 1 B). The relative cerebral blood flow (rCBF) was
recovered gradually to about >80% in the Ntg mice and
about 70% in the GET-1 mice after 20 minutes. Ntg
mice showed significantly higher rCBF when compared
with the GET-1 mice during the reperfusion time points
of 10, 12 and 14 minutes (Ntg: 50.6 ± 8.4, 55.9 ± 6.5,
66.5 ± 6.3 vs GET-1: 26.9 ± 3.8, 34.1 ± 4.8, 43.6 ± 6.1, n = 9,
*P < 0.05 by Mann–Whitney test). In the sham groups, no
changes of rCBF were observed in both Ntg and GET-1
mice (~ 100%) and at all time points, the rCBF of sham
groups was significantly higher than the SAH-induced
group (data not shown).
GET-1 mice exhibited more severe neurological
dysfunction than the Ntg mice after SAH
The neurological deficits of the Ntg and GET-1 mice
were evaluated for 3 days after SAH. As indicated in the
neurological deficit score, the Ntg mice exhibited the
greatest neurological dysfunction on Day 1 after SAH
(40.0± 7.5; n = 10) and recovered gradually on Day 2
(31.1± 7.6; n = 10) and Day 3 (23.1± 6.4; n = 10). In the
GET-1 mice, the neurological dysfunction on Day 1 after
SAH was 56.8± 8.1(n = 10) and the mice gradually recov-
ered on Day 2 (51.7.1± 7.0; n = 10) and Day 3 (39.2± 5.3;
n = 10). During the whole period of neurological deficit
assessment, GET-1 mice showed higher dysfunction
compared to Ntg mice after SAH, with a significantdifference on Day 2 (*P < 0.05 by Mann–Whitney test)
(Figure 1C).
GET-1 mice were more susceptible to blood-brain barrier
(BBB) breakdown than Ntg mice after SAH
To further understand the role of astrocytic ET-1 in
SAH-induced neurological dysfunction in GET-1 mice,
the BBB integrity in both Ntg and GET-1 mice was in-
vestigated with Evans Blue (EB) extravasation experi-
ment (Figure 2A). At 24 hours after SAH, the amount of
EB leakage was increased in NTg and GET-1 mice when
compared with their sham groups. Most importantly, a
significant elevation of EB leakage was observed in GET-1
brains (Ntg: 2.42 ± 0.54 μg/hemisphere vs GET-1: 5.74 ±
0.87 μg/hemisphere, n = 8, **P < 0.01 by Mann–Whitney
test) (Figure 2A), indicating increased BBB permeability
and more BBB breakdown in the brains of GET-1 mice
after SAH.
GET-1 mice accumulated more water in their brains than
the Ntg mice after SAH, and SR 49059 significantly
reduced the water content in the GET-1 mice after SAH
GET-1 mice brains showed more severe BBB breakdown,
suggesting that those mice experienced more severe
vasogenic edema after SAH. A significant difference was
observed in the cerebral water content between the Ntg
and the GET-1 mice (Ntg: 78.0 ± 0.20%; GET-1: 79.60 ±
0.23%; *P < 0.05 by Mann–Whitney test) suggesting that
the GET-1 mice were more susceptible to SAH-induced
cerebral edema (Figure 2B).
A previous study reported that arginine vasopressin
(AVP) V2 receptor antagonist ameliorates cytotoxic
edema and SAH-induced cerebral edema formation [35].
To investigate whether another subtype of vasopressin
receptor is also involved in SAH-induced vasogenic
edema development, V1a receptor antagonist, SR 49059,
was tested. A significant reduction of cerebral water
content was observed in both Ntg and GET-1 mice
treated with SR 49059 when compared with their ve-
hicle-treated group (Ntg vehicle-treated: 78.03 ± 0.18%;
Ntg SR 49059-treated: 77.24 ± 0.21%, GET-1 vehicle-
treated: 79.68 ± 0.20%; GET-1 SR 49059-treated: 78.60 ±
0.21%, *P < 0.05 by Mann–Whitney test) (Figure 2B).
For both genotypes, all mice survived 24 hours after
SR 49059 treatment.
Upregulation of endothelin-1 (ET-1) in the wild-type mice
brain after SAH
To investigate whether ET-1 is involved in the patho-
physiology of SAH, the expression level of ET-1 was
examined by the immunocytochemical analysis. After
SAH, the Ntg brains showed a significant upregulation
of ET-1 expression in the hippocampal region, where as-
trocytes are highly re-activated under stress conditions,
Figure 1 Effects of subarachnoid hemorrhage induction in Ntg and GET-1 mice after subarachnoid hemorrhage. (A) Kaplan-Meier
curves show the survival data of the Ntg (solid line, n = 10) and the GET-1 (broken line, n = 13) mice after subarachnoid hemorrhage. (B) Line
graph shows the cerebral blood flow of Ntg and GET-1 mice during SAH. (C) Histogram comparing the neurological deficit scores for the
Ntg (white bar) and GET-1 (black bar) mice after SAH for 3 days. (*P < 0.05, Mann-Whitey test; n = 10 for Ntg and GET-1 mice).
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that astrocytic ET-1 played a role in the pathophysiology
of SAH condition (Figure 2C).
Increased glial fibrillary acidic protein (GFAP) in the GET-1
mice brain after SAH
To further understand the role of over-expressing astro-
cytic ET-1 in the pathogenesis after SAH, immunocyto-
chemistry was used to determine the expression and
cellular location of GFAP.GFAP is an intermediate filament cytoskeletal protein
expressed primarily by astroglia. Increased expression of
GFAP represents astroglial activation and gliosis in many
neurodegenerative diseases; therefore, GFAP has been
used as an indicator of brain injury [36-38]. After SAH,
both Ntg and GET-1 brains showed a significant in-
crease in the GFAP expression in the hippocampal
region when compared with their sham control. At a
higher magnification, GFAP-labeled astrocytes were
stained brownish and appeared star-shaped. The GFAP
Figure 2 GET-1 mice showed more severe brain edema with upregulation of ET-1 and GFAP expressions after subarachnoid
hemorrhage. (A) Analysis the integrity of the BBB with the EB extravasation in Ntg and GET-1 brain after SAH. (*P < 0.05, ANOVA followed by
Bonferroni’s test; n = 4 for the sham groups and n = 8 for the SAH groups). (B) Histogram comparing the water content of the Ntg and GET-1
mice with or without SR 49059 treatment after SAH (*P < 0.05, ANOVA followed by Bonferroni’s test; n = 4 for each group of mice). (C)
Immunocytochemical analysis of ET-1 expression in Ntg brain after SAH. Representative micrograph shows the expression of ET-1 in the
hippocampal region of the Ntg brain after Sham (i) and SAH (ii) (n = 4 for each group). Histogram below shows the quantification results (relative
value in percentage) of ET-1 Sham and SAH of Ntg brain sections using software ImageJ. (**P < 0.01, student t-test; n = 4 for each group of mice).
(D) Immunocytochemical analysis of GFAP expression after SAH. Representative micrograph shows the localization and expression of GFAP in the
astrocytes of the hippocampus of the Ntg and GET-1 brain at (i-iv) low and (v-viii) high magnification (n = 4 for each group). The GFAP signals in
the astrocytes at the SAH groups of the Ntg and GET-1 brains is increased, and they have longer processes (arrowheads). Histogram below shows
the quantification results (relative value in percentage) of GFAP Sham and SAH of Ntg and GET-1 brain sections using software ImageJ. (*P < 0.05,
**P < 0.01, ***P < 0.005, ANOVA followed by Bonferroni’s test; n = 4 for each group of mice).
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more intense and widespread in the hippocampal region
compared to the Ntg mice. Furthermore, longer astro-
cytic processes were observed in the GET-1 mice brains
(Figure 2D).
GET-1 mice exhibited a more severe vasospasm after SAH
To investigate the role of astrocytic ET-1 on SAH-induced
vasospasm, MCAs were isolated and examined from both
genotypes after SAH. Vasospasm in the MCA was ob-
served in both Ntg and GET-1 when compared to their
sham groups, and the MCA in the brains of the GET-1
mice showed more severe constrictions compared to the
Ntg mice (Sham: Ntg 126.2 ± 7.4 μm vs GET-1 132.2 ±
10.4 μm; SAH: Ntg 106.5 ± 2.3 μm vs GET-1 99.7 ± 3.1 μm,
n = 5, *P < 0.05 by Mann–Whitney test) (Figure 3A).
Immunocytochemical studies of NOS expression in MCA
Nitric oxide (NO), also known as an Endothelium-Derived
Relaxing Factor, which is generated by vascular endothe-
lium and is one of the important factors that regulatessmooth muscle tone [39]. nNOS is produced in the adven-
titia and eNOS is produced in intima [40], and studies have
shown that both neuronal (nNOS) and endothelial nitric
oxide synthase (eNOS) depletion underlies vasospasm
[39,41]. ICC was performed to investigate the expression of
NOs in GET-1 mice brains after SAH. After SAH, the ex-
pression of nNOS in the layer of adventitia (arrows) of
MCA was reduced in both genotypes when compared to
their sham groups. Significant reduction in nNOS was ob-
served in the MCA of GET-1 mice compared to the Ntg
mice after SAH (Figure 3B). Furthermore, both eNOS and
p-eNOS expressions were significantly reduced in both of
Ntg and GET-1 MCA after SAH compared to their sham
groups. Additionally, p-eNOS expression of GET-1 MCA
after SAH was significantly reduced when compared to
that of Ntg MCA (Figure 3C and D).
GET-1 mice showed an upregulation of PKC-α/phospho-
PKC-α expression in the brain after SAH
In SAH, ET-1 induces the development of vasospasm
through enhancement of PKC-α activity, and the
Figure 3 Vasospasm analysis and NOS expressions in MCA after subarachnoid hemorrhage. (A) Representative pictures show the
histological analysis of MCA. Vasospasm is observed in both Ntg and GET-1 brain after SAH when compared to that of their sham group (n = 5).
Histogram shows the arterial diameter measurement of MCA in Ntg and GET-1 after SAH. (*P < 0.05, Mann-Whitey test; n = 5 for Ntg and GET-1
mice). Expression of NOS in MCA after SAH. Representative photos shows the (B) nNOS, (C) eNOS and (D) p-eNOS expressions of sham and SAH
of MCA in Ntg and GET-1 brain. Arrowheads show the expression of nNOS (tunica adventitia) and eNOS/p-eNOS (tunica intima), (n = 4 for each
group of mice). Histograms show the quantification results (relative value in percentage) of immunocytochemistry of sham and SAH of Ntg and
GET-1 MCA sections. (*P < 0.05, **P < 0.01, ANOVA followed by Bonferroni’s test; n = 4 for each group of mice).
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[42,43]. To investigate whether PKC-α mediates astro-
cytic ET-1 induced downregulation of NOS, Western
blot analysis was performed. Significant upregulation of
PKC-α and p-PKC-α was observed in the brain of both
Ntg and GET-1 mice after SAH when compared to their
sham groups (Ntg Sham: 100 ± 3.7% vs Ntg SAH: 119.7 ±
4.6%, P < 0.05; GET-1 Sham: 100.5 ± 3.7% vs GET-1 SAH:
135.8 ± 1.6% P < 0.01, Mann–Whitney test; n = 4). Signifi-
cant difference was observed between Ntg and GET-1
mice brain after SAH (Ntg SAH; 119.7 ± 4.6% vs GET-1
SAH 135.8 ± 1.6% P < 0.05, Mann–Whitney test; n = 4)
(Figure 4).GET-1 MCA showed downregulation of potassium
channels after SAH
The vascular tone of the smooth muscle is regulated by
the K+ membrance conductance and studies have shown
that reduced expression of the potassium channels might
contribute to vasospasm after SAH [44,45]. To investi-
gate the expression of the Ca2+-activated K+ channel in
the MCA after SAH, immunocytochemical analysis was
performed. Significant downregulation of Ca2+-activated
K+ channel expression was observed in both Ntg and
GET-1 MCA after SAH compared to their sham groups.
GET-1 MCA after SAH showed a significant reduction
of Ca2+-activated K+ channel expression compared to
Figure 4 Western blot analysis of PKC-α and p-PKC-α in Ntg and GET-1 brain after SAH. Representative blots show PKC-α and p-PKC-α
expression in the sham and SAH groups of Ntg and GET-1 brain. Histogram below shows the quantification (relative percentage) of the Western
blot. (*P < 0.05, **P < 0.01, Mann-Whitey test; n = 4 for Ntg and GET-1 mice).
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ET-1 mediated-SAH induces a more severe dysfunction
of K+ channel that might lead to cerebral vasospasm.
ETA receptor antagonist ameliorated vasospasm after SAH
ET-1 is one of the important factors in development of
vasospasm after SAH and plays a role in vascular tone of
smooth muscle contraction through ETA receptor [46].
ETA receptor is localized in the vascular smooth muscle
cells and mediates vascular contraction [47]. When com-
pared to their sham groups, the expression of ETA re-
ceptor only slightly increased in the smooth muscle cells
(tunica media) (arrows) in both Ntg and GET-1 MCA
after SAH (Figure 5B). To determine if ETA receptor
plays a role in the development of vasospasm, ABT-627,Figure 5 Immunocytochemical analysis of Ca2+-activated K+ channel a
Representative micrograph shows the localization and expression of Ca2+-a
from each group of mice). Histogram shows the quantification results (rela
Ntg and GET-1 MCA sections. (*P < 0.05, **P < 0.01, ***P < 0.005, ANOVA fol
Representative micrograph shows the localization and expression of ETAR i
Histogram shows the quantification results (relative value in percentage) of
sections. (*P < 0.05, **P < 0.01, ANOVA followed by Bonferroni’s test; n = 3 f
immunocytochemical expressions of PKC-α and the diameters of MCA afte
measurements of MCA diameter. (*P < 0.05, **P < 0.01, Mann-Whitey test; na competitive ETA receptor anatagonist, was adminis-
trated 5 mins after onset of SAH. Treatment with ABT-
627 resulted in an improvement in neurological deficits
and reduced infarct size after MCAO in GET-1 mice. In
Figure 5C, down-regulation of PKC-α was observed in
both Ntg and GET-1 MCA after ABT-627 treatment
when compared to the vehicle controls. In addition,
ABT-627 treatment significantly ameliorated vasospasm
in the MCA of both GET-1 and Ntg mice compared to
their vehicle controls. ABT-627 treatment resulted in a
more promising improvement in GET-1 mice when
compared to Ntg mice (Ntg SAH: 114.5 ± 4.9 μm vs
Ntg SAH+ABT-627: 133.5 ± 5.1 μm; GET-1 SAH:
104.7 ± 3.1 μm vs GET-1 SAH+ABT-627: 138.6 ±
1.0 μm, *P < 0.05, **P < 0.01 Mann–Whitney test; n = 3).nd ETAR expressions in Ntg and GET-1 MCA after SAH. (A)
ctivated K+ channel in the MCA of the Ntg and GET-1 after SAH. (n = 3
tive value in percentage) of immunocytochemistry of sham and SAH of
lowed by Bonferroni’s test; n = 3 for each group of mice). (B)
n the smooth muscle cells (arrows) of MCA in Ntg and GET-1 mice.
immunocytochemistry of sham and SAH of Ntg and GET-1 MCA
or each group of mice). (C) Representative micrograph shows the
r treating with ETAR antagonist ABT-627. Histogram below shows the
= 3 for Ntg and GET-1 mice).
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ever, did not show any effect in either genotypes (data not
shown).
Discussion
Elevation of ET-1 levels in the cerebrospinal fluid after
SAH have been reported in SAH patients [18]. ET-1 is
known to be a potent endothelium-derived vasocon-
stricting agent [48]. In the CNS, ET-1 can be produced
by astrocytes, neurons and pituitary cells under normal
physiological conditions [12,14,49]. ET-1 is also released
from endothelial and smooth muscle cells when stimu-
lated by thrombin and oxyhemoglobin [8,50]. However,
to date the source and the release mechanisms of ET-1
are still largely unknown. In order to address whether
astrocytic ET-1 plays a role in the development of cere-
bral edema and vasospasm after SAH, transgenic mice
over-expressing ET-1 in astrocytes (GET-1) was used to
exaggerate the effects of ET-1 during SAH and delayed
ischemia after SAH. The GET-1 mice (from 1 week to
20 weeks old) show higher endothelin-1 mRNA and
peptide levels in the brain when compared to Ntg brains.
In spite of the increased level of astrocytic ET-1, GET-1
mice appear normal under physiological condition. The
cerebrovasculature and the mean artery blood pressure
is similar in the GET-1 compared to the Ntg mice, sug-
gesting that the GET-1 mice show no significant differ-
ence in the cerebral artery under normal physiological
condition [20]. Although GET-1 mice have been shown
to have higher endothelin-1 mRNA and peptide levels in
the brain when compared to Ntg brains [20], their cere-
brovasculatures showed no significant difference to that
of Ntg brains. We speculate that the insignificant in-
creased level of ET-1 in GET-1 mice may not cause any
exacerbating effects on cerebral vasospasm and edema
formation; however, these mice will be more susceptible
to these pathophysiological processes under stress condi-
tions, such as SAH when astrocytic ET-1 level will be in-
creased substantially.
Vasopressin levels increase in the plasma and cerebro-
spinal fluid after SAH, suggesting that the antidiuretic
hormone plays a critical role in edema development
[51]. SR 49059 is considered to be the most potent and
selective non-peptide V1a receptor antagonist in both
animals and human [52,53]. Recently, SR 49059 was
shown to reduce intracerebral hemorrhagic brain injury-
induced cerebral edema in mice [54]. In the present
study, arterial puncture technique was used to induce
subarachnoid hemorrhage, and GET-1 mice developed
more severe brain damage and edema after this proced-
ure. SR 49059 was administrated intraperitoneally to the
NTg and GET-1 mice to evaluate the effect of vasopres-
sin V1a receptor antagonist in the edema formation after
SAH. The results showed that SR 49059 significantlyreduced brain water content in both Ntg and GET-1
mice 24 hours after SAH, which is in agreement with a
previous study [55] despite using a different type of
hemorrhagic stroke model and paradigm. Collectively,
these data suggest that SR 49059 is a promising drug in
treating hemorrhagic brain edema and provide a strong
rationale to investigate the drug in clinical settings.
Although many studies have reported that ET-1 levels
are increased in plasma and CSF during ischemic and
hemorrhagic stroke [56,57], it is still unclear whether the
production and release of ET-1 is the primary response
of the brain cells (astrocytes, endothelial cells, neurons)
to the stroke, or the secondary response in which activa-
tion of the sympathoadrenal system increases the plasma
catecholamine and vasopressin levels [58], which stimu-
lates the release of ET-1 from the peripheral organs. In
the present study, over-expression of astrocytic ET-1 in
GET-1 mice resulted in a more severe brain damage and
vasospasm, suggesting that astrocytes may be one of the
major sources of ET-1 production and release under
pathological conditions. Previous in vitro data suggested
that the SAH-induced hypoxia-ischemia in astrocytes ac-
counts for the ET-1 release into the subarachnoid space
[56]. The present report provides the first documenta-
tion for the significance of astrocytic ET-1 in haemor-
rhagic stroke in an animal model. Our data demonstrate
that overexpression of astrocytic ET-1 excerbates several
pathophysiological processes after SAH, and this could
be a contributing factor to these processes together with
the physiological levels of astrocytic ET-1, however, we
could not directly conclude that this is the case. Further
studies in animals, such as with targeted deletion of
astrocytic ET-1, will be required before drawing the
conclusion.
In agreement with other studies, we demonstrate that
astrocytic ET-1 also induces vasospasm with a concur-
rent elevation of PKC-α protein expression and activa-
tion [43,59,60]. ET-1 regulates the vascular tone of the
cerebral blood vessels through its receptor subtypes,
ETA and ETB. ETB receptors are known to mediate vaso-
dilation upon localization to the endothelial cells of
blood vessels. A recent study shows that the expression
of ETB receptors is regulated by initial cerebral blood
flow through the MEK-ERK1/2 signaling pathway [61].
ETA receptors are mainly found in smooth muscle cells
and are involved in vasoconstriction; therefore, they are
crucial in cerebral vasospasm [62]. In the present study,
immunocytochemical analysis of ETA receptor expres-
sion in MCA showed an insignificant change in both
Ntg and GET-1 after SAH, which is in agreement with
the previous finding that the expression of smooth-
muscle ETA receptors and their mRNA level is un-
changed or slightly increased in the cerebral arteries
after SAH [63,64]. It is demonstrated that an increased
Yeung et al. BMC Neuroscience 2013, 14:131 Page 11 of 14
http://www.biomedcentral.com/1471-2202/14/131coupling of the smooth muscle ETA receptor with the
second cascade probably contributes to the development
of cerebral vasospasm [64]. ETA receptor antagonists
have been used in numerous studies in alleviating
SAH-induced cerebral vasospasm [65-67]. However,
other studies have also reported that ETA receptor an-
tagonists have the potential adverse effects such as
hypotension and pneumonia. Moreover, there are no sig-
nificant differences in mortality or improving outcomes
in the phase 3 clinical trials investigating ETA receptor
antagonists as a therapeutic strategy for vasospasm
[68-71]. However, ETA receptor antagonists, such as cla-
zosentan, have been used in alleviating SAH-induced
cerebral vasospasm [72]. In a clinical study, only high
doses of clazosentan resulted in a significantly reduced
vasospasm-related morbidity or all-cause mortality
within 6 weeks post SAH, but not at longer time points
[69], suggesting that ETA receptor antagonist could be
used for treating vasospasm. However, the interference
by other drugs taken by the patients during the clinical
study may reduce the efficiency of the clazosentan at a
later time point. In the current study, ETA receptor an-
tagonist ABT-627 effectively attenuated SAH-induced
vasospasm in both Ntg and GET-1 mice, and suggestedFigure 6 Proposed mechanism of astrocytic ET-1 mediated cerebral v
more severe neurological deficits and vasospasm after SAH. Increased astro
receptor and mediated by PKC-α, which leads to dynfunction in the K+ cha
the SAH-induced vasospasm. The impairment of NO system also exaggerat
edema and BBB breakdown that further contributes to cerebral vasoconstr
reduced the SAH-induced edema, suggesting that astrocytic ET-1 induces ethat pathways elicited by astrocytic ET-1 through ETA
receptor, but not ETB receptor, are involved in SAH-
induced vasospasm. ABT-627 is reported to greatly im-
prove neurological deficits and reduce infarct size in
mice after ischemic stroke, suggesting that the drug
could normalize the vasoconstriction effect of ET-1 [28],
as shown in the present study. Although a few ETA
receptor antagonists have been shown to have adverse
effects in the SAH patients, we cannot rule out the pos-
sibility that there are pharmacological differences among
ETA receptor antagonists as well as testing conducted
under non-optimized conditions. Here we report an-
other possible ETA receptor antagonist candidate, ABT-
627, which may be an alternative therapeutic drug for
treating SAH-induced vasospasm.
ET-1 stimulates the ETB receptor and increases NO
production [73]. NO is suggested to reverse the effects
of the ET-1-induced vasoconstriction, by negative feed-
back and reducing the level of ET-1 [73,74]. Diminished
production of NO and increased release of ET-1, there-
fore, are suggested to be the vital consequences of vaso-
spasm in SAH [75]. It is reported that endothelial nitric
oxide synthase (eNOS) expression as well as NO pro-
duction are impaired by the elevated ET-1 level throughasospasm after SAH. GET-1 mice with over-expressed in ET-1 showed
cytic ET-1 during SAH induces cerebral vasospasm through the ETA
nnels. Administration of ETA receptor antagonist ABT-627 ameliorates
es the vasospasm effect. Astrocytic ET-1 leads to more severe cerebral
iction. Vasopressin V1a receptor antagonist, SR 49059, significantly
dema in SAH through vasopressin V1a receptor.
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duces vascular relaxation by inhibiting PKC activity, the
reduced NO production after SAH, therefore, enhances
the PKC-dependent vasoconstriction [76]. Also, elevated
level of ET-1 activates ETA receptor and decreases the
vascular sensitivity to NO by a PKC-independent path-
way [77]. Down-regulation of PKC-α was observed in
both Ntg and GET-1 MCA after ETA receptor antagonist
ABT-627 treatment (Figure 5C), suggesting that astro-
cytic ET-1 induced vasospasm is also mediated through
ETA receptor and PKC. These data collectively provide a
strong rationale to investigate ABT-627 as a therapeutic
drug to treat SAH-induced vasospasm.
K+ channels are important in regulating the membrane
potential of arterial smooth muscle. Large conductance
Ca2+-activated K+ channel is one of the channels that is
found in the arterial smooth muscle and contributes to
the resting membrane potential [45]. Recently, the
function and expression of ion channels, particularly the
Ca2+-activated K+ channels, have been investigated in
SAH-induced vasospasm. In the present study, the ex-
pression of Ca2+-activated K+ channels in MCA was
largely reduced after SAH in both Ntg and GET-1 mice,
which is in agreement with others findings that elevated
PKC activity after SAH causes dysfunction in K+ channel
activity and expression [78,79].
Here we propose the possible mechanism of the astro-
cytic ET-1 mediated cerebral vasospasm after SAH
(Figure 6). The astrocytic ET-1 induces cerebral vaso-
spasm through the ETA receptor, which leads to an
upregulation of PKC-α.Conclusions
To the best of our knowledge, this is the first study to
elucidate the role of astrocytic ET-1 in vasogenic edema
formation and vasospasm development in SAH-induced
brain injured mice. Both the vasopressin V1a receptor
antagonist, SR 49059, and ETA receptor inhibitor, ABT-
627 significantly ameliorated the astrocytic ET-1 induced
complications after SAH. These potential therapeutic
drugs could be used in future for treating SAH patients.
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